Ekso Bionics Holdings Q2 2024 GAAP EPS $(0.13) Beats $(0.14) Estimate, Sales $4.950M Miss $5.171M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ekso Bionics Holdings (NASDAQ:EKSO) reported Q2 2024 GAAP EPS of $(0.13), beating the estimate of $(0.14). However, sales of $4.950M missed the $5.171M estimate, though they increased by 5.25% year-over-year.
July 29, 2024 | 8:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ekso Bionics Holdings reported a better-than-expected EPS of $(0.13) for Q2 2024, beating the $(0.14) estimate. However, sales of $4.950M missed the $5.171M estimate, despite a 5.25% year-over-year increase.
The better-than-expected EPS is a positive sign, but the miss on sales estimates and the relatively small year-over-year sales increase may neutralize the impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100